BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma C, Guizzetti L, Jairath V. Improving Clinical Trial Efficiency in Gastroenterology. Gastroenterology 2019;157:892-3. [DOI: 10.1053/j.gastro.2019.02.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Macaluso FS, Maida M, Ventimiglia M, Renna S, Cottone M, Orlando A. Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Inflamm Bowel Dis 2019;25:987-97. [PMID: 30590590 DOI: 10.1093/ibd/izy365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
4 Ma C, Choi MY. Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00432-5. [PMID: 34856197 DOI: 10.1016/S2468-1253(21)00432-5] [Reference Citation Analysis]
5 Ma C, Panaccione NR, Nguyen TM, Guizzetti L, Parker CE, Hussein IM, Vande Casteele N, Khanna R, Dulai PS, Singh S, Feagan BG, Jairath V. Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis 2019;13:1201-16. [PMID: 31111881 DOI: 10.1093/ecco-jcc/jjz087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
6 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
7 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. J Crohns Colitis 2021:jjab135. [PMID: 34309658 DOI: 10.1093/ecco-jcc/jjab135] [Reference Citation Analysis]
9 Sedano R, Jairath V, Ma C; IBD Trial Design Group. Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology 2022;162:1005-18. [PMID: 34998800 DOI: 10.1053/j.gastro.2021.12.284] [Reference Citation Analysis]
10 Chateau T, Le Berre C, Peyrin-Biroulet L. Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases? Clin Gastroenterol Hepatol 2020;18:1030-2. [PMID: 31589974 DOI: 10.1016/j.cgh.2019.09.036] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Enck P, Klosterhalfen S. The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:641436. [PMID: 33867990 DOI: 10.3389/fphar.2021.641436] [Reference Citation Analysis]
12 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
13 Singh S. Evolution of Clinical Trials in Inflammatory Bowel Diseases. Curr Gastroenterol Rep 2018;20:41. [PMID: 30078058 DOI: 10.1007/s11894-018-0648-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
14 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Ma C, Sedano R, Almradi A, Casteele NV, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology 2021;160:2291-302. [PMID: 33610533 DOI: 10.1053/j.gastro.2021.02.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Enck P, Klosterhalfen S. Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders. Front Psychiatry 2020;11:797. [PMID: 33192627 DOI: 10.3389/fpsyt.2020.00797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Klonarakis M, Andrews CN, Raman M, Panaccione R, Ma C. Review article: therapeutic targets for the pharmacologic management of coeliac disease-the future beyond a gluten-free diet. Aliment Pharmacol Ther 2022;55:1277-96. [PMID: 35229332 DOI: 10.1111/apt.16846] [Reference Citation Analysis]
18 Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. J Crohns Colitis 2021;15:551-66. [PMID: 32898223 DOI: 10.1093/ecco-jcc/jjaa176] [Reference Citation Analysis]
19 Kornbluth A. Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? Inflamm Bowel Dis 2020;26:1730-2. [PMID: 32031216 DOI: 10.1093/ibd/izz333] [Reference Citation Analysis]
20 Zeng J, Wang Z, Yang X. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03312-3] [Reference Citation Analysis]
21 Murray EJ. Editorial: Demystifying the Placebo Effect. Am J Epidemiol 2021;190:2-9. [PMID: 32719871 DOI: 10.1093/aje/kwaa162] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
23 Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31674-8. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]